Gene expression profiling in anaplastic large cell lymphoma and Hodgkin's disease

Leukemia & Lymphoma
Pascal TrempatPierre Brousset

Abstract

Recent efforts have been made to isolate molecular targets that could explain different outcome between histological subtypes of lymphomas and to understand the molecular mechanisms underlying oncogenic events. Using the SSH technique, we compared the transcriptome of 2 cases of ALK+ and ALK- anaplastic large cell lymphoma (ALCL) and of 2 cases of classical Hodgkin's lymphoma (cHL) with opposite behavior. Regarding ALCL, we showed that ALK-positive tumors overexpressed genes involved in different signaling pathways such as activation or signaling of T-cells, regulation of apoptosis, phospholipase Cgamma and phosphatidyl inositol-3 Kinase. In addition, the characterization of a specific molecular signature may be of clinical relevance since ALK+ tumors generally have a better prognosis than ALK- ones. Similar problems of differential prognosis is observed in cases of cHL, which in addition, may be morphologically and immunologically indistinguishable. Therefore, we applied the same SSH technique to 2 cHL samples from patients with favorable and poor outcome, respectively. Forty-four cDNAs were significantly overexpressed in the poor outcome case. In addition to the defender against death cell 1 (DAD1) gene, overexpressed clones ...Continue Reading

References

Jun 11, 1996·Proceedings of the National Academy of Sciences of the United States of America·L DiatchenkoP D Siebert
Sep 12, 1998·Molecular Cell·J M DesterroR T Hay
Sep 2, 1999·Biochemical and Biophysical Research Communications·T Nishimoto
Mar 1, 2000·Trends in Biochemical Sciences·M R Wilson, S B Easterbrook-Smith
May 9, 2000·The Journal of Biological Chemistry·L MilonM L Lacombe
May 24, 2000·Proceedings of the National Academy of Sciences of the United States of America·C R YangD A Boothman
Aug 10, 2000·The American Journal of Pathology·M RedondoC K Petito
May 5, 2001·The American Journal of Pathology·C VillalvaP Brousset
Jun 8, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·P K Epling-BurnetteS Wei
May 2, 2002·Journal of Hematotherapy & Stem Cell Research·Timo GaiserKarin Lange
Jun 21, 2002·The New England Journal of Medicine·Andreas RosenwaldUNKNOWN Lymphoma/Leukemia Molecular Profiling Project
Aug 16, 2002·British Journal of Haematology·Claire VillalvaPierre Brousset
Sep 11, 2002·American Journal of Clinical Pathology·George Z RassidakisL Jeffrey Medeiros
Feb 27, 2003·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Sven de VosH Phillip Koeffler
May 20, 2003·The Journal of Pathology·George Z RassidakisL Jeffrey Medeiros
Jul 3, 2003·Proceedings of the National Academy of Sciences of the United States of America·Hiroshi NishiharaLars Eckmann
Sep 25, 2003·Nature Reviews. Molecular Cell Biology·Jacob-S Seeler, Anne Dejean
Nov 25, 2003·Oncogene·Peter ListonRobert G Korneluk

❮ Previous
Next ❯

Citations

Dec 22, 2007·Nature Reviews. Cancer·Roberto ChiarleGiorgio Inghirami
Sep 19, 2012·Neuroendocrinology·Ola Nilsson
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roberto PivaGiorgio Inghirami

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis